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A	  rescue	  by	  chaperones	  
	  
Joost	  Schymkowitz	  &	  Frederic	  Rousseau	  
	  
Protein	  aggregation	  is	  associated	  to	  more	  than	  50	  human	  pathologies	  
including	  prevalent	  diseases	  such	  as	  Alzheimer	  and	  Parkinson	  disease.	  A	  
phenotypic	  screen	  in	  Escherichia	  coli	  associating	  antibiotic	  resistance	  to	  
the	  inhibition	  of	  protein	  aggregation	  now	  allows	  screening	  for	  chemical	  
inhibitors	  of	  protein	  aggregation	  in	  a	  simple,	  fast	  and	  inexpensive	  manner.	  
	  
	  
Protein	  misfolding	  and	  aggregation	  have	  been	  associated	  to	  a	  growing	  list	  of	  
pathologies	  including	  neurodegenerative	  diseases,	  systemic	  and	  organ-­‐specific	  
amyloidoses1	  but	  also	  metabolic	  diseases	  and	  cancer2.	  Protein	  misfolding	  and	  
aggregation	  result	  in	  disease	  through	  protein	  loss-­‐of-­‐function	  but	  additionally,	  
aggregated	  proteins	  often	  also	  acquire	  toxic	  properties	  through	  mechanisms	  that	  
still	  remain	  unclear.	  What	  is	  known	  however	  is	  that	  aggregation	  results	  from	  the	  
self-­‐assembly	  by	  β-­‐strand	  interactions	  of	  short	  aggregation-­‐prone	  amino	  acid	  
segments	  within	  a	  protein	  chain3.	  When	  a	  protein	  is	  in	  its	  native	  conformation	  
these	  aggregation	  sensitive	  sequences	  are	  generally	  buried	  in	  the	  hydrophobic	  
core	  where	  they	  are	  protected	  from	  aggregation	  by	  numerous	  native	  
interactions.	  Familial	  aggregation	  diseases	  such	  as	  lysozyme	  amyloidosis	  	  	  are	  
caused	  by	  mutations	  that	  destabilize	  the	  native	  conformation	  of	  the	  protein	  
thereby	  increasing	  the	  fraction	  of	  solvent-­‐exposure	  of	  the	  aggregation-­‐prone	  
protein	  segments.	  However,	  for	  many	  aggregation-­‐related	  pathologies,	  	  including	  
Alzheimer’s	  and	  Parkinson’s,	  the	  sporadic	  form	  of	  the	  disease	  is	  the	  most	  
prevalent	  by	  far.	  Here	  the	  wild	  type	  protein	  is	  affected	  by	  aggregation	  as	  a	  result	  
of	  age-­‐related	  decline	  in	  the	  ability	  to	  efficiently	  remove	  misfolded	  proteins,	  for	  
instance	  during	  processes	  such	  as	  protein	  synthesis	  and	  translocation4.	  	  
	  
One	  of	  the	  main	  strategies	  explored	  to	  treat	  aggregation-­‐related	  diseases	  
consists	  of	  identifying	  chemical	  chaperones,	  i.e.	  compounds	  that	  inhibit	  protein	  
aggregation	  by	  direct	  interaction	  with	  the	  affected	  protein5.	  Chemical	  
chaperones	  can	  be	  envisaged	  to	  work	  by	  several	  means.	  First,	  chemical	  
chaperones	  could	  inhibit	  protein	  misfolding	  by	  (kinetic)	  stabilisation	  of	  the	  
native	  structure.	  This	  strategy	  has	  lead	  to	  the	  development	  of	  Tafamidis6	  that	  
inhibits	  mutant	  transthyrethin	  amyloidosis,	  but	  is	  also	  being	  explored	  for	  several	  
lysosomal	  storage	  disorders7	  such	  as	  Gaucher	  disease.	  Second,	  chemical	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chaperones	  could	  also	  inhibit	  or	  modify	  the	  self-­‐assembly	  of	  aggregation-­‐prone	  
sequences	  thereby	  lowering	  aggregate	  toxicity	  or	  facilitating	  their	  degradation	  
by	  the	  cell.	  	  
	  
As	  promising	  as	  chemical	  chaperones	  appear,	  their	  development	  is	  fraught	  with	  
practical	  and	  technical	  obstacles.	  As	  a	  result	  only	  one	  chemical	  chaperone	  has	  
made	  it	  to	  the	  market	  so	  far.	  One	  major	  barrier	  is	  the	  disordered	  nature	  of	  many	  
disease-­‐associated	  aggregating	  protein	  impeding	  strategies	  aiming	  at	  stabilizing	  
native	  structures.	  Further,	  in	  vitro	  assays	  require	  relatively	  large	  amounts	  of	  
purified	  protein,	  which	  can	  be	  limiting	  when	  working	  with	  aggregating	  proteins.	  
Moreover,	  these	  assays	  typically	  monitor	  aggregation	  using	  conformational	  dyes	  
such	  as	  ThT	  that	  can	  potentially	  interfere	  with	  compound	  binding	  and	  efficacy..	  
Finally,	  it	  is	  often	  difficult	  to	  produce	  homogenous	  starting	  samples	  consisting	  
only	  of	  non-­‐aggregated	  protein,	  affecting	  experimental	  reproducibility.	  Perhaps	  
counterintuitively,	  in	  vivo	  assays	  in	  yeast	  or	  mamalian	  cell	  culture	  also	  have	  
important	  limitations	  when	  it	  comes	  to	  protein	  aggregation.	  Many	  aggregation	  
diseases	  involve	  extracellular	  aggregation.	  Assays	  requiring	  cellular	  uptake	  will	  
therefore	  limit	  the	  available	  chemical	  space,	  while	  the	  reducing	  environment	  of	  
the	  cytoplasm	  is	  not	  ideally	  suited	  to	  screen	  for	  aggregation	  in	  an	  oxidative	  
milieu.	  	  
	  
In	  this	  issue	  Saunders	  et	  al8	  have	  pushed	  forward	  an	  in	  vivo	  assay	  in	  E.coli	  they	  
previously	  developed	  to	  screen	  for	  mutations	  that	  optimise	  protein	  stability	  in	  E.	  
coli9	  and	  cleverly	  adapted	  it	  to	  allow	  screening	  for	  the	  inhibition	  of	  amyloid	  
aggregation.	  Originally,	  the	  assay	  consists	  of	  a	  tripartite	  β-­‐lactamase	  fusion	  
construct	  linking	  the	  activity	  of	  split	  β	  -­‐lactamase	  and	  thus	  ampicillin	  resistance	  
to	  the	  structural	  stability	  of	  the	  target	  protein	  (Figure	  1).	  However,	  as	  mentioned	  
above	  many	  aggregating	  proteins	  involved	  in	  human	  disease	  are	  intrinsically	  
disordered	  and	  their	  aggregation-­‐prone	  sequences	  cannot	  be	  protected	  from	  
aggregation	  by	  stabilizing	  the	  native	  state.	  Expressing	  the	  Islet	  Amyloid	  
Polypeptide	  and	  the	  Alzheimer	  β-­‐amyloid	  peptide	  the	  authors	  demonstrate	  that	  
the	  same	  tripartite	  β	  -­‐lactamase	  fusion	  can	  be	  used	  to	  link	  the	  amyloid	  assembly	  
of	  aggregation	  prone	  sequence	  peptides	  to	  antibiotic	  resitance.	  They	  further	  
validate	  the	  utility	  of	  this	  phenotypic	  assay	  for	  screening	  compounds	  that	  modify	  
the	  aggregation	  of	  IAPP.	  An	  additional	  advantage	  of	  the	  assay	  resides	  in	  the	  
periplasmic	  localisation	  of	  the	  reporter	  system	  which	  provides	  both	  compound	  
accessibility	  and	  an	  oxidative	  environment.	  	  
	  
A	  potential	  danger	  from	  a	  reporter	  screen	  on	  antibiotic	  resistance	  is	  the	  
possibility	  that	  hit	  compounds	  do	  not	  act	  directly	  on	  the	  aggregating	  protein	  of	  
interest,	  but	  instead	  alter	  proteostasis	  of	  the	  periplasm.	  The	  authors	  addressed	  
this	  by	  coupling	  their	  phenotypic	  screen	  to	  electrospray	  
ionisation-­‐mass	  spectrometry	  linked	  to	  ion	  mobility	  spectrometry	  (ESI-­‐IMS-­‐
MS)10	  analysis	  of	  hit	  compounds,	  a	  method	  that	  provides	  a	  snapshot	  of	  the	  
complex	  soup	  of	  species	  that	  accumulates	  during	  the	  aggregation	  process.	  This	  
not	  only	  allows	  to	  discern	  compounds	  that	  directly	  bind	  to	  the	  target	  protein,	  but	  
also	  provides	  information	  on	  exactly	  what	  aggregating	  species	  is	  bound	  and	  how	  
this	  affects	  the	  composition	  of	  the	  reaction	  mixture.	  The	  combination	  of	  both	  
these	  techniques	  creates	  an	  exciting	  opportunity	  to	  search	  for	  novel	  molecules	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that	  can	  modulate	  protein	  aggregation,	  but	  also	  highlights	  the	  challenge	  of	  
creating	  chemicals	  that	  combine	  the	  seemingly	  contradictory	  properties	  of	  
specifically	  interacting	  with	  hydrophobic	  surfaces	  involved	  in	  aggregation	  while	  










Figure	  1:	  	  Tripartite	  β-­‐lactamase	  screening	  assay	  against	  aggregation.	  β-­‐
lactamase	  function,	  and	  thus	  ampicillin	  resistance,	  is	  restored	  when	  aggregation	  
of	  the	  target	  protein	  is	  inhibited.	  This	  can	  occur	  either	  through	  stabilization	  of	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